Effect of the CYP2C19 genotype on the pharmacokinetics of icotinib in healthy male volunteers

European Journal of Clinical Pharmacology

Volumn 68, Issue 12, 2012, Pages 1677-1680

  Ruan, Can Jun ^a   Liu, Dong Yang ^a   Jiang, Ji ^a   Hu, Pei ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

CYP2C19; Icotinib; Pharmacokinetics

Indexed keywords

CYTOCHROME P450 2C19; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GENOMIC DNA; ICOTINIB; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHINESE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; URTICARIA; WILD TYPE;

ADULT; ALLELES; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CROWN ETHERS; GENOTYPE; HUMANS; MALE; PROTEIN KINASE INHIBITORS; QUINAZOLINES;

EID: 84871268132     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1288-4     Document Type: Article

References (17)

1. Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, De Placido S, Bianco AR, Tortora G (2001) Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 7(5):1459- 1465
2. Ren GJ, Zhao YY, Zhu YJ, Xiao Y, Xu JS, Shan B, Zhang L (2011) Tumor gene mutations and messenger RNA expression: correlation with clinical response to icotinib hydrochloride in non-small cell lung cancer. Chinese Med J 124(1):19-25
3. Desta Z, Zhao X, Shin JG, Flockhart DA (2002) Clinical significance of the cytochrome P450 2 C19 genetic polymorphism. Clin Pharmacokinet 41(12):913-958
4. Myrand SP, Sekiguchi K, Man MZ, Lin X, Tzeng RY, Teng CH, Hee B, Garrett M, Kikkawa H, Lin CY, Eddy SM, Dostalik J, Mount J, Azuma J, Fujio Y, Jang IJ, Shin SG, Bleavins MR, Williams JA, Paulauskis JD, Wilner KD (2008) Pharmacokinetics/ genotype associations for major cytochrome P450 enzymes in native and first- and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin Pharmacol Ther 84(3):347-361 doi:10.1038/sj.clpt.6100482
5. Li-Wan-Po A, Girard T, Farndon P, Cooley C, Lithgow J (2010) Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19 z.ast;17. Br J Clin Pharmacol 69 (3):222-230 doi:10.1111/j.1365-2125.2009.03578.x
6. Xiao ZS, Goldstein JA, Xie HG, Blaisdell J, Wang W, Jiang CH, Yan FX, He N, Huang SL, Xu ZH, Zhou HH (1997) Differences in the incidence of the CYP2C19 polymorphism affecting the Smephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther 281(1):604-609
7. De Morais SM, Goldstein JA, Xie HG, Huang SL, Lu YQ, Xia H, Xiao ZS, Ile N, Zhou HH (1995) Genetic analysis of the Smephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 58(4):404-411 doi:10.1016/0009-9236(95)90053-5
8. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA (1994) Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46(4):594-598
9. Liu D, Jiang J, Hu P, Tan F, Wang Y (2009) Quantitative determination of icotinib in human plasma and urine using liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 877(30):3781-3786 doi:10.1016/ j.jchromb.2009.08.055
10. Liu D, Jiang J, Zhang L, Tan F, Wang Y, Hu P (2011) Metabolite characterization of a novel anti-cancer agent, icotinib, in humans through liquid chromatography/quadrupole time-of-flight tandem mass spectrometry. Rapid communications in mass spectrometry : RCM 25(15):2131-2140 doi:10.1002/rcm.5061
11. Baldwin RM, Ohlsson S, Pedersen RS, Mwinyi J, Ingelman-Sundberg M, Eliasson E, Bertilsson L (2008) Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. Br J Clin Pharmacol 65 (5):767-774 doi:10.1111/j.1365-2125.2008.03104.x
12. Bohanec Grabar P, Grabnar I, Rozman B, Logar D, Tomsic M, Suput D, Trdan T, Peterlin Masic L, Mrhar A, Dolzan V (2009) Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4- (trifluoromethyl)phenyl]- 2-butenamide (A77 1726) pharmacokinetics in leflunomidetreated patients with rheumatoid arthritis. Drug metabolism and disposition: the biological fate of chemicals 37(10):2061-2068 doi:10.1124/dmd.109.027482
13. Lee JB, Lee KA, Lee KY (2011) Cytochrome P450 2 C19 polymorphism is associated with reduced clopidogrel response in cerebrovascular disease. Yonsei Med J 52(5):734-738 doi:10.3349/ ymj.2011.52.5.734
14. Brennan M, Williams JA, Chen Y, Tortorici M, Pithavala Y, Liu YC (2011) Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics. Eur J Clin Pharmacol doi:10.1007/s00228-011-1171-8
15. Zalloum I, Hakooz N, Arafat T (2011) Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole.Mol Biol Rep 39:4195-4200 doi:10.1007/s11033-011- 1204-5
16. Barker CM, Murray SS, Teirstein PS, Kandzari DE, Topol EJ, Price MJ (2010) Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity. JACC Cardiovasc Interv 3(10):1001-1007 doi:10.1016/j.jcin.2010.07.012
17. Shi HY, Yan J, Zhu WH, Yang GP, Tan ZR, Wu WH, Zhou G, Chen XP, Ouyang DS (2010) Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism. Eur J Clin Pharmacol 66(11):1131-1136 doi:10.1007/ s00228-010-0869-3